High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients

Lorente, L. (Leonardo); Martin, M.M. (María M.); Ramos, L. (Luis); Argueso, M. (Mónica); Caceres, J.J. (Juan J.); Sole-Violan, J. (Jordi); Jimenez, A. (Alejandro); Borreguero-Leon, J.M. (Juan María); González-Rivero, A. (Agustín F.); Orbe, J. (Josune); Rodriguez, J.A. (José Antonio); Paramo, J.A. (José Antonio)

Keywords:

TIMP-1
Ischemic stroke
Patients
Mortality
Prognosis

Issue Date:

2019

Publisher:

Springer Science and Business Media LLC

ISSN:

1471-2377

Note:

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Citation:

Lorente, L. (Leonardo); Martin, M.M. (María M.); Ramos, L. (Luis); et al. "High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients". BMC Neurology. 19 (167), 2019, 2019

Abstract

Background: Higher circulating levels of tissue inhibitor of matrix metalloproteinases (TIMP)-1 early after ischemic stroke have been associated with lower survival. The objectives of this study were to determine serum TIMP-1 levels during the first week of a severe cerebral infarction in surviving and non-surviving patients, and whether those levels during the first week could be used as a mortality biomarker for these patients. Methods: We included patients with severe malignant middle cerebral artery infarction (MMCAI) defined as computer tomography showing ischaemic changes in more than 50% of the middle cerebral artery territory and Glasgow Coma Scale (GCS) ≤ 8. We measured serum levels of matrix metalloproteinases (MMP)-9 and TIMP-1. End-point study was 30-day mortality. Results: We found higher TIMP-1 concentrations at days 1 (p < 0.001), 4 (p = 0.001), and 8 (p = 0.03) of MMCAI in nonurviving (n = 34) than in surviving (n = 34) patients. We found lower serum MMP-9 concentrations at day 1 (p = 0.03) of MMCAI and no significant differences at days 4 and 8. ROC curve analysis of TIMP-1 concentrations performed at days 1, 4, and 8 of MMCAI showed an area under curve to predict 30-day mortality of 81% (p < 0.001), 80% (p < 0.001) and 72% (p = 0.07) respectively. Conclusions: The new findings of our study were that non-surviving MMCAI patients showed higher serum TIMP-1 levels during the first week of MMCAI that surviving patients, and those levels during the first week of MMCAI could be used as mortality biomarkers.

URI:

https://hdl.handle.net/10171/63272

DOI:

10.1186/s12883-019-1401-8

Appears in Collections:

DA - CIMA - Enfermedades cardiovasculares - Aterosclerosis e inflamación - Artículos de revista

Files in This Item: